Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) EVP Nikita Shah sold 146,403 shares of the business’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total transaction of $2,563,516.53. Following the completion of the sale, the executive vice president directly owned 253,390 shares of the company’s stock, valued at $4,436,858.90. This represents a 36.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Amneal Pharmaceuticals Trading Down 2.2%
Shares of AMRX traded down $0.39 during trading hours on Thursday, hitting $17.27. The company had a trading volume of 2,244,046 shares, compared to its average volume of 2,168,140. Amneal Pharmaceuticals, Inc. has a 52-week low of $9.15 and a 52-week high of $19.26. The company has a quick ratio of 1.44, a current ratio of 2.20 and a debt-to-equity ratio of 77.65. The stock’s 50 day moving average price is $17.08 and its 200 day moving average price is $14.54. The firm has a market cap of $5.51 billion, a P/E ratio of 35.24 and a beta of 1.27.
Analyst Upgrades and Downgrades
Several analysts have weighed in on the company. Weiss Ratings upgraded Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, July 29th. Wall Street Zen upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, July 12th. UBS Group lifted their target price on shares of Amneal Pharmaceuticals from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Barclays upped their price target on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $21.00 price target on shares of Amneal Pharmaceuticals in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $17.67.
Institutional Investors Weigh In On Amneal Pharmaceuticals
Institutional investors and hedge funds have recently bought and sold shares of the business. Globeflex Capital L P bought a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter worth approximately $2,536,000. Bank of New York Mellon Corp bought a new position in shares of Amneal Pharmaceuticals during the second quarter valued at approximately $17,573,000. Handelsbanken Fonder AB raised its holdings in shares of Amneal Pharmaceuticals by 3.0% during the second quarter. Handelsbanken Fonder AB now owns 76,400 shares of the company’s stock valued at $1,322,000 after acquiring an additional 2,200 shares in the last quarter. Bank of America Corp DE lifted its stake in Amneal Pharmaceuticals by 50.0% in the first quarter. Bank of America Corp DE now owns 676,795 shares of the company’s stock worth $8,413,000 after acquiring an additional 225,637 shares during the period. Finally, Arkadios Wealth Advisors bought a new stake in Amneal Pharmaceuticals in the first quarter valued at $4,165,000. Hedge funds and other institutional investors own 31.82% of the company’s stock.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.
Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.
Featured Stories
- Five stocks we like better than Amneal Pharmaceuticals
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
